Epix Medical of Cambridge, MA, has started phase II clinical trials for breast indications of its MS-325 MRI contrast agent. Epix and marketing partner Mallinckrodt of St. Louis are already investigating MR angiography uses for MS-325, which illuminates
Epix Medical of Cambridge, MA, has started phase II clinical trials for breast indications of its MS-325 MRI contrast agent. Epix and marketing partner Mallinckrodt of St. Louis are already investigating MR angiography uses for MS-325, which illuminates blood vessels on an MRI scan. The companies believe that the agent could also be useful for breast cancer detection, due to the increased vascularity of breast tumors. The phase II trial will test the safety and feasibility of MS-325 for detecting and characterizing benign and malignant breast lesions. MS-325 is in phase II clinical trials for peripheral vascular and carotid MRA, and is in a phase II feasibility trial for coronary MRA, according to Epix president Michael Webb.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.